592 related articles for article (PubMed ID: 27147580)
1. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers.
Derks S; Liao X; Chiaravalli AM; Xu X; Camargo MC; Solcia E; Sessa F; Fleitas T; Freeman GJ; Rodig SJ; Rabkin CS; Bass AJ
Oncotarget; 2016 May; 7(22):32925-32. PubMed ID: 27147580
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms.
Nakano H; Saito M; Nakajima S; Saito K; Nakayama Y; Kase K; Yamada L; Kanke Y; Hanayama H; Onozawa H; Okayama H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Goto A; Kono K
Sci Rep; 2021 Jan; 11(1):1982. PubMed ID: 33479394
[TBL] [Abstract][Full Text] [Related]
3. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features.
Liu X; Choi MG; Kim K; Kim KM; Kim ST; Park SH; Cristescu R; Peter S; Lee J
Pathol Res Pract; 2020 Apr; 216(4):152881. PubMed ID: 32089413
[TBL] [Abstract][Full Text] [Related]
4. The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: A systematic review.
Bos J; Groen-van Schooten TS; Brugman CP; Jamaludin FS; van Laarhoven HWM; Derks S
Cancer Treat Rev; 2024 Jun; 127():102737. PubMed ID: 38669788
[TBL] [Abstract][Full Text] [Related]
5. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
Zhang L; Wang Y; Li Z; Lin D; Liu Y; Zhou L; Wang D; Wu A; Li Z
Diagn Pathol; 2021 May; 16(1):38. PubMed ID: 33933102
[TBL] [Abstract][Full Text] [Related]
7. Microsatellite instability and Epstein-Barr virus combined with PD-L1 could serve as a potential strategy for predicting the prognosis and efficacy of postoperative chemotherapy in gastric cancer.
Yang N; Wu Y; Jin M; Jia Z; Wang Y; Cao D; Qin L; Wang X; Zheng M; Cao X; Jiang J
PeerJ; 2021; 9():e11481. PubMed ID: 34046266
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological characteristics and prognosis of Epstein-Barr virus-associated gastric cancer.
Li LL; Yu AY; Zhu M; Ma LY; Cao MH; Liu WL; Qin XB; Gao C; Han ZX; Wang HM
Arch Virol; 2024 May; 169(5):114. PubMed ID: 38700535
[TBL] [Abstract][Full Text] [Related]
9. Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer.
Panda A; Mehnert JM; Hirshfield KM; Riedlinger G; Damare S; Saunders T; Kane M; Sokol L; Stein MN; Poplin E; Rodriguez-Rodriguez L; Silk AW; Aisner J; Chan N; Malhotra J; Frankel M; Kaufman HL; Ali S; Ross JS; White EP; Bhanot G; Ganesan S
J Natl Cancer Inst; 2018 Mar; 110(3):316-320. PubMed ID: 29155997
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan.
Yoshida T; Ogura G; Tanabe M; Hayashi T; Ohbayashi C; Azuma M; Kunisaki C; Akazawa Y; Ozawa S; Matsumoto S; Suzuki T; Mitoro A; Fukunaga T; Shimizu A; Fujimoto G; Yao T
Cancer Biol Ther; 2022 Dec; 23(1):191-200. PubMed ID: 35220884
[TBL] [Abstract][Full Text] [Related]
11. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.
Kim YB; Ahn JM; Bae WJ; Sung CO; Lee D
Int J Cancer; 2019 Aug; 145(4):916-926. PubMed ID: 30664822
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic Features and Prognostic Significance of Immunohistochemistry and In Situ Hybridization Based Molecular Classification in Gastric Carcinoma.
Issin G; Sayar İ; Demir F; Bakkaloğlu İG; Gamsizkan M; Yildiz Z; Yilmaz I; Özmen SA; Çağatay DV; Zemheri IE; Demiriz M; Günal A
J Environ Pathol Toxicol Oncol; 2023; 42(4):1-14. PubMed ID: 37522564
[TBL] [Abstract][Full Text] [Related]
13. Clinical Significance of Tumor and Immune Cell PD-L1 Expression in Gastric Adenocarcinoma.
Kim DH; Bae GE; Suh KS; Ryuman D; Song KS; Kim JS; Lee SI; Yeo MK
In Vivo; 2020; 34(6):3171-3180. PubMed ID: 33144421
[TBL] [Abstract][Full Text] [Related]
14. EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions.
Sasaki S; Nishikawa J; Sakai K; Iizasa H; Yoshiyama H; Yanagihara M; Shuto T; Shimokuri K; Kanda T; Suehiro Y; Yamasaki T; Sakaida I
Gastric Cancer; 2019 May; 22(3):486-496. PubMed ID: 30264329
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas.
Yoon CJ; Chang MS; Kim DH; Kim W; Koo BK; Yun SC; Kim SH; Kim YS; Woo JH
Gastric Cancer; 2020 Sep; 23(5):780-795. PubMed ID: 32206940
[TBL] [Abstract][Full Text] [Related]
16. Human Leukocyte Antigen Class I Deficiency in Gastric Carcinoma: An Adaptive Immune Evasion Strategy Most Common in Microsatellite Instable Tumors.
Iwasaki A; Shinozaki-Ushiku A; Kunita A; Yamazawa S; Sato Y; Yamashita H; Fukayama M; Seto Y; Ushiku T
Am J Surg Pathol; 2021 Sep; 45(9):1213-1220. PubMed ID: 34310369
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis.
Gu L; Chen M; Guo D; Zhu H; Zhang W; Pan J; Zhong X; Li X; Qian H; Wang X
PLoS One; 2017; 12(8):e0182692. PubMed ID: 28796808
[TBL] [Abstract][Full Text] [Related]
18. Young-onset gastric cancer and Epstein-Barr Virus (EBV) - a major player in the pathogenesis?
Moore A; Hikri E; Goshen-Lago T; Barkan T; Morgenstern S; Brook E; Maderer A; Roth W; Gordon N; Kashtan H; Brenner B; Moehler M; Aharon IB
BMC Cancer; 2020 Jan; 20(1):34. PubMed ID: 31937281
[TBL] [Abstract][Full Text] [Related]
19. Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein-Barr Virus-associated gastric carcinoma.
Nakayama A; Abe H; Kunita A; Saito R; Kanda T; Yamashita H; Seto Y; Ishikawa S; Fukayama M
PLoS One; 2019; 14(1):e0211358. PubMed ID: 30695048
[TBL] [Abstract][Full Text] [Related]
20. Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type.
Koh J; Nam SK; Roh H; Kim J; Lee BC; Kim JW; Ahn SH; Park DJ; Kim HH; Park KU; Chung JH; Kim WH; Lee HS
Genes Chromosomes Cancer; 2019 Jan; 58(1):12-22. PubMed ID: 30239046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
